Animal models play crucial role in the continuous experimental activities present into biomedical research field. The availability of in vivo models is especially important in proof of principle experiments and development of preclinical safety & efficacy data commonly required for progressing the human clinical trials. The mice models are important tool for the understanding of neurogenerative disorders such as Alzheimer and Parkinson’s diseases. The neurogenerative disorders are invariably fatal for the treatment; the estimated cost incurred by the Americans for treating patients on Medicare and Medicaid is enormous, estimated $279 billion in 2017. However, very little is yet understood about what causes Alzheimer’s diseases, as there is no appropriate drug or treatment available. Therefore, the appropriate development of drug molecule is in demand for the treatment of such diseases. “Meticulous Research” in its latest publication states that, the “global market for mice model is expected to grow at a CAGR of 7.2% from 2018 to 2023 to reach $1,370.4 million by 2023.”
This growth is primarily driven by continuing modification in mice model for cancers, immune diseases, and rare diseases; increasing devouring of personalized medicine propelling the demand for humanized mice model; rising grants and investments for biological research; rising pharmaceutical R&D activities; and increasing focus of International Mouse Phenotyping Consortium (IMPC) and International Knockout Mouse Consortium (IKMC) on the development of embryonic stem cells as well as knockout and mutant mice.
Personalized medicine provides better therapies to patients through use of information about the patients that better predicts treatment response before undergoing treatment. In recent years, animal models were used as surrogates of human biology due to the logistical and ethical restrictions of working with cell and tissue samples from human donors. Thus, small animals such as mice and rats are widely used mammalian model systems due to their small size, ease of maintenance and handling, a short reproductive cycle, sharing of genomic and physiological properties with humans, and ability to be readily manipulated genetically.
The immunodeficient mice engrafted with functional human cells and tissues, i.e., ―humanized mice‖, have become increasingly important as a small pre-clinical animal model for the study of human diseases. Humanized mice are permitting significant progress in studies of human infectious disease, cancer, regenerative medicine, graft versus host disease, allergies, and immunity. Ultimately, use of humanized mice may lead to the implementation of truly ―personalized‖ medicine in the clinic. According to the Personalized Medicine Coalition (PMC), in 2016, there were 132 FDA approved drugs present in the market compared to only 5 approved drugs in 2008. As the personalized medicine is emerging rapidly across the globe, within a decade, it went from 5% of the FDA pipeline in 2005 to 25% in 2015.
The rising prevalence of chronic and infectious diseases globally is demanding for the better drug molecule according to the genetic makeup of an individual patient. According to the Tufts Center for the Study of Drug Development, in 2015, biopharmaceutical companies nearly doubled their R&D investment in personalized medicines over the past five years and expect to increase their investment by an additional 33% in the next five years. In addition, researchers also predict a 69% increase in the number of personalized medicine in development over the next five years. Thus, increasing R&D funding, and production of personalized medicine from pharmaceutical companies is strongly demanding the animal research model to conduct clinical trials to understand the safety and efficacy of drug molecules.
The report provides meticulous analysis of mice model market by segmenting it on the basis of type (inbred mice, outbred mice, genetically engineered mice), service (breeding, rederivation), therapeutic area (oncology, heart disease), technology (crispr cas9, scnt), mice care product (cage, feed), end user, and geography.
The key players analyzed in the Mice Model Market are Charles River Laboratories International, Inc. (U.S.), The Jackson Laboratory (U.S.), Laboratory Corporation of America Holdings (U.S.), Horizon Discovery Group plc (U.K.), Trans Genic Inc. (Japan), genOway (France), Taconic Biosciences, Inc. (U.S.), Envigo (U.S.), JANVIER LABS (France), Ingenious Targeting Laboratory (U.S.), and Harbour Antibodies BV (The Netherlands).
Key Topics Covered in This Report:
- Research Methodology
- Executive Summary
- Market Share Analysis
- Market Insights
- Global Mice Model Market, By Type
- Global Mice Model Services Market, By Type
- Global Mice Model Market, By Therapeutic Area
- Global Mice Model Market, By Technology
- Global Mice Care Products Market, By Type
- Global Mice Model Market, By End User
- Geographic Analysis
- Competitive Landscape
- Company Profiles
Download detailed Table of Content here: https://www.meticulousresearch.com/download-sample-report/?cp_id=4151